Abstract
Hyperacmoses A–C, three seco-norpolyprenylated acylphloroglucinols (PPAPs) ( 1 – 3 ), along with two processors ( 4 and 5 ), were purified from Hypericum acmosepalum . Structurally, compounds 1 and 2 represent the first seco-norPPAP with an unprecedented 5/6/5/6/5 pentacyclic framework, while compound 3 is the first seco-norPPAP with a 5/5/6/6 tetracyclic core. Three rare PPAPs had the same biosynthetic precursor, and Baeyer–Villiger oxidation of this precursor at different positions could finally give different types of PPAPs ( 1 – 3 ). Four compounds ( 1, 2, 4, and 5 ) exhibited a better triglyceride (TG) inhibitory effect than atorvastatin in oleic acid-induced HepG2 cells. The compound with the highest potential, compound 1, could prohibit the expression of lipid synthesis proteins, FASN and ACACA, by targeting ACSS2.
Abstract from the paper’s OpenAlex record, shown for indexing and research. Copyright remains with the authors or the publisher. Read at the source ↗
The text the model read, with the source record’s inline markup (italics, sub- and superscripts) rendered and its character entities decoded; quote offsets refer to the raw text.
Claims 10
Claim · model-written summary
Hyperacmoses A–C and two precursor compounds were purified from Hypericum acmosepalum.
- Taxon
- Hypericum acmosepalumHypericum acmosepalume0
- Outcome
- Hyperacmoses A–Ce0
- Qualifier
- two processors ( 4 and 5 )e0
Verbatim
e0“Hyperacmoses A–C, three seco-norpolyprenylated acylphloroglucinols (PPAPs) ( 1 – 3 ), along with two processors ( 4 and 5 ), were purified from Hypericum acmosepalum”
Claim · model-written summary
Compounds 1 and 2 have the first reported seco-norPPAP 5/6/5/6/5 pentacyclic framework.
- Taxon
- Hypericum acmosepalumHypericum acmosepalume1
- Outcome
- 5/6/5/6/5 pentacyclic frameworke0
- Qualifier
- first seco-norPPAPe0
Verbatim
e0“compounds 1 and 2 represent the first seco-norPPAP with an unprecedented 5/6/5/6/5 pentacyclic framework”
e1“Hypericum acmosepalum”
Claim · model-written summary
Compound 3 has the first reported seco-norPPAP 5/5/6/6 tetracyclic core.
- Taxon
- Hypericum acmosepalumHypericum acmosepalume1
- Outcome
- 5/5/6/6 tetracyclic coree0
- Qualifier
- first seco-norPPAPe0
Verbatim
e0“compound 3 is the first seco-norPPAP with a 5/5/6/6 tetracyclic core”
e1“Hypericum acmosepalum”
Claim · model-written summary
Three rare PPAPs shared a biosynthetic precursor.
- Taxon
- Hypericum acmosepalumHypericum acmosepalume1
- Outcome
- same biosynthetic precursore0
Verbatim
e0“Three rare PPAPs had the same biosynthetic precursor”
e1“Hypericum acmosepalum”
Claim · model-written summary
The authors propose that oxidation at different precursor positions could yield different PPAP types.
- Taxon
- Hypericum acmosepalumHypericum acmosepalume1
- Outcome
- different types of PPAPs ( 1 – 3 )e0
- Qualifier
- Baeyer–Villiger oxidation of this precursor at different positionse0
Verbatim
e0“Baeyer–Villiger oxidation of this precursor at different positions could finally give different types of PPAPs ( 1 – 3 )”
e1“Hypericum acmosepalum”
Claim · model-written summary
Compound 1 inhibited triglycerides in oleic acid-induced HepG2 cells better than atorvastatin.
- Treatment
- 1e0
- Outcome
- triglyceride (TG) inhibitory effecte0
- Direction
- bettere0
- Comparator
- atorvastatine0
- Setting
- oleic acid-induced HepG2 cellse0
Not reportedTaxon
Verbatim
e0“Four compounds ( 1, 2, 4, and 5 ) exhibited a better triglyceride (TG) inhibitory effect than atorvastatin in oleic acid-induced HepG2 cells”
Claim · model-written summary
Compound 2 inhibited triglycerides in oleic acid-induced HepG2 cells better than atorvastatin.
- Treatment
- 2e0
- Outcome
- triglyceride (TG) inhibitory effecte0
- Direction
- bettere0
- Comparator
- atorvastatine0
- Setting
- oleic acid-induced HepG2 cellse0
Not reportedTaxon
Verbatim
e0“Four compounds ( 1, 2, 4, and 5 ) exhibited a better triglyceride (TG) inhibitory effect than atorvastatin in oleic acid-induced HepG2 cells”
Claim · model-written summary
Compound 4 inhibited triglycerides in oleic acid-induced HepG2 cells better than atorvastatin.
- Treatment
- 4e0
- Outcome
- triglyceride (TG) inhibitory effecte0
- Direction
- bettere0
- Comparator
- atorvastatine0
- Setting
- oleic acid-induced HepG2 cellse0
Not reportedTaxon
Verbatim
e0“Four compounds ( 1, 2, 4, and 5 ) exhibited a better triglyceride (TG) inhibitory effect than atorvastatin in oleic acid-induced HepG2 cells”
Claim · model-written summary
Compound 5 inhibited triglycerides in oleic acid-induced HepG2 cells better than atorvastatin.
- Treatment
- 5e0
- Outcome
- triglyceride (TG) inhibitory effecte0
- Direction
- bettere0
- Comparator
- atorvastatine0
- Setting
- oleic acid-induced HepG2 cellse0
Not reportedTaxon
Verbatim
e0“Four compounds ( 1, 2, 4, and 5 ) exhibited a better triglyceride (TG) inhibitory effect than atorvastatin in oleic acid-induced HepG2 cells”
Claim · model-written summary
Compound 1 suppressed FASN and ACACA protein expression by targeting ACSS2.
Not reportedTaxon
Verbatim
e0“compound 1, could prohibit the expression of lipid synthesis proteins, FASN and ACACA, by targeting ACSS2”